Levosimendan mediates the BMP/Smad axis through upregulation of circUSP34-targeted miR-1298 to alleviate pulmonary hypertension

Qiang Meng,Linhong Song,Hui Wang,Gang Wang,Gengxu Zhou
DOI: https://doi.org/10.1186/s12931-024-02945-5
IF: 5.8
2024-08-22
Respiratory Research
Abstract:Pulmonary hypertension (PH) is a long-term disease that impacts approximately 1% of the world's population. Currently, levosimendan (Lev) is proposed for PH treatment. However, the mechanism of Lev in the treatment of PH is unknown.
respiratory system
What problem does this paper attempt to address?